Profile data is unavailable for this security.
About the company
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.
- Revenue in USD (TTM)3.95bn
- Net income in USD680.80m
- Incorporated1999
- Employees9.60k
- LocationDexcom Inc6340 Sequence DrSAN DIEGO 92121-4356United StatesUSA
- Phone+1 (858) 200-0200
- Fax+1 (302) 636-5454
- Websitehttps://www.dexcom.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hologic Inc | 4.03bn | 789.50m | 18.28bn | 6.99k | 23.71 | 3.56 | 16.64 | 4.54 | 3.32 | 3.32 | 16.97 | 22.09 | 0.4406 | 2.72 | 6.57 | -- | 8.63 | 13.12 | 9.84 | 15.20 | 56.25 | 60.82 | 19.59 | 24.75 | 3.03 | 64.45 | 0.3307 | -- | -0.0025 | 3.66 | 73.14 | -- | 4.30 | -- |
| Insulet Corp | 1.98bn | 420.90m | 18.38bn | 3.00k | 45.55 | 16.44 | 36.83 | 9.26 | 5.75 | 5.75 | 25.96 | 15.94 | 0.7223 | 1.42 | 6.14 | 661,300.00 | 15.32 | 2.71 | 18.56 | 3.14 | 69.36 | 65.81 | 21.22 | 4.28 | 2.80 | 98.71 | 0.5557 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
| Cooper Companies Inc | 3.80bn | 359.30m | 19.90bn | 15.00k | 55.64 | 2.51 | 27.03 | 5.23 | 1.80 | 1.80 | 19.02 | 39.80 | 0.3196 | 1.70 | 5.56 | 253,606.70 | 3.02 | 10.06 | 3.29 | 11.34 | 66.36 | 65.54 | 9.45 | 29.00 | 1.18 | 5.46 | 0.2493 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 0.00 |
| Steris PLC | 5.12bn | 602.62m | 21.30bn | 18.18k | 35.51 | 3.23 | 19.23 | 4.16 | 6.08 | 4.38 | 51.62 | 66.80 | 0.4758 | 3.86 | 5.49 | 281,655.40 | 5.62 | 5.19 | 6.10 | 5.68 | 43.01 | 43.64 | 11.81 | 10.97 | 1.55 | 8.29 | 0.2528 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
| Zimmer Biomet Holdings Inc | 7.60bn | 1.08bn | 21.58bn | 18.00k | 20.65 | 1.75 | 10.48 | 2.84 | 5.25 | 5.25 | 36.87 | 62.00 | 0.3538 | 0.9136 | 5.38 | 421,972.20 | 5.05 | 2.21 | 5.82 | 2.52 | 71.78 | 71.25 | 14.28 | 7.28 | 0.6987 | 7.52 | 0.3425 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| Illumina Inc | 4.39bn | -1.58bn | 21.73bn | 10.59k | -- | 10.25 | -- | 4.95 | -10.00 | -10.00 | 27.61 | 13.36 | 0.5441 | 2.66 | 6.17 | 414,542.00 | -19.63 | -6.20 | -23.16 | -7.28 | 63.94 | 66.39 | -36.08 | -15.48 | 1.85 | 38.44 | 0.4834 | -- | -1.75 | 6.21 | 73.64 | -- | -7.91 | -- |
| Waters Corp | 2.91bn | 622.64m | 21.88bn | 7.90k | 35.16 | 13.65 | 26.86 | 7.53 | 10.48 | 10.48 | 48.89 | 27.00 | 0.645 | 2.20 | 4.47 | 367,740.10 | 13.82 | 19.77 | 16.72 | 25.29 | 59.73 | 58.45 | 21.43 | 23.38 | 1.38 | 10.11 | 0.5325 | 0.00 | -0.5229 | 4.09 | -9.26 | 1.53 | 4.72 | -- |
| West Pharmaceutical Services Inc. | 2.88bn | 499.60m | 23.24bn | 10.60k | 47.55 | 8.45 | 36.64 | 8.08 | 6.75 | 6.75 | 38.86 | 37.96 | 0.7743 | 4.50 | 5.51 | 271,358.50 | 13.02 | 15.61 | 15.16 | 18.65 | 34.87 | 38.06 | 16.81 | 18.47 | 2.23 | -- | 0.0695 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| DexCom Inc | 3.95bn | 680.80m | 29.08bn | 9.60k | 45.45 | 14.70 | 32.56 | 7.36 | 1.64 | 1.64 | 9.52 | 5.07 | 0.6107 | 2.76 | 4.42 | 411,875.00 | 10.51 | 8.30 | 14.28 | 10.50 | 62.10 | 65.90 | 17.22 | 14.14 | 2.12 | -- | 0.5579 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| IDEXX Laboratories, Inc. | 3.84bn | 866.24m | 34.27bn | 11.00k | 40.38 | 21.22 | 34.54 | 8.91 | 10.36 | 10.36 | 46.00 | 19.72 | 1.19 | 3.85 | 7.14 | 349,528.80 | 26.91 | 28.00 | 38.86 | 43.49 | 60.72 | 58.74 | 22.53 | 21.35 | 1.03 | 59.10 | 0.3507 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Veeva Systems Inc | 2.57bn | 615.26m | 34.74bn | 7.17k | 55.66 | 6.70 | 53.30 | 13.50 | 3.85 | 3.85 | 15.69 | 32.04 | 0.4453 | -- | 6.27 | 358,846.80 | 10.65 | 11.97 | 12.97 | 15.36 | 73.35 | 72.00 | 23.91 | 23.74 | -- | -- | 0.00 | 0.00 | 9.68 | 22.35 | 7.79 | 18.00 | 21.68 | -- |
| Resmed Inc | 4.81bn | 1.11bn | 35.76bn | 9.98k | 32.29 | 6.88 | 27.73 | 7.44 | 7.54 | 7.54 | 32.59 | 35.39 | 0.6886 | 2.17 | 6.08 | 481,711.90 | 15.94 | 14.24 | 18.11 | 16.53 | 57.67 | 56.85 | 23.15 | 20.35 | 1.91 | 44.71 | 0.1154 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.34 |
| GE HealthCare Technologies Inc | 19.56bn | 1.68bn | 37.46bn | 51.00k | 22.46 | 4.50 | 16.20 | 1.92 | 3.65 | 3.65 | 42.63 | 18.20 | 0.5906 | 5.40 | 4.41 | 383,490.20 | 5.22 | -- | 6.97 | -- | 41.33 | -- | 8.84 | -- | 0.982 | 5.67 | 0.5478 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Agilent Technologies Inc | 6.50bn | 1.41bn | 37.94bn | 17.40k | 27.46 | 6.43 | 22.82 | 5.84 | 4.81 | 4.81 | 22.14 | 20.53 | 0.5996 | 2.87 | 5.06 | 358,950.30 | 13.04 | 11.00 | 16.13 | 13.25 | 54.75 | 53.29 | 21.75 | 18.01 | 1.37 | 55.86 | 0.3319 | 21.46 | -0.219 | 6.82 | -1.12 | 7.39 | 10.98 | 8.86 |
Data as of Nov 21 2024. Currency figures normalised to Dexcom Inc's reporting currency: US Dollar USD
41.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 45.61m | 11.68% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 24.18m | 6.19% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 17.95m | 4.60% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 16.67m | 4.27% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 15.02m | 3.85% |
| Sands Capital Management LLCas of 30 Sep 2024 | 10.32m | 2.64% |
| Geode Capital Management LLCas of 30 Sep 2024 | 9.94m | 2.54% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 7.63m | 1.95% |
| Jennison Associates LLCas of 30 Sep 2024 | 6.93m | 1.78% |
| TIAA-CREF Investment Management LLCas of 30 Sep 2024 | 6.47m | 1.66% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
